Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Covid-19 associated Guillain-Barre Syndrome: Contrasting tale of four patients from a tertiary care centre in India

Satyan Nanda, Rahul Handa *, Atul Prasad, Rajiv Anand, Dhruv Zutshi, Sujata K. Dass, Prabhjeet Kaur Bedi, Aarti Pahuja, Pankaj Kumar Shah, Bipan Sharma
Department of Neurology, BLK Super Speciality Hospital, New Delhi, India

A R T I C L E   I N F O
Article history:
Received 16 July 2020
Received in revised form 1 September 2020
Accepted 10 September 2020

A B S T R A C T
Background: Globally, more than 12 million people have been infected with COVID − 19 infection till date with more than 500,000 fatalities. Although, Covid-19 commonly presents with marked respiratory symptoms in the form of cough and dyspnoea, a neurotropic presentation has been described of late as well.
Objective: In this brief communication we report four cases of Covid-19 who presented to our hospital with features suggestive of Guillain-Barre Syndrome (GBS).
Discussion: The mechanisms by which SARS-CoV-2 causes neurologic damage are multifaceted, including direct damage to specific receptors, cytokine-related injury, secondary hypoxia, and retrograde travel along nerve fibres. The pathogenesis of GBS secondary to Covid-19 is not well understood. It is hypothesised that viral illnesses related GBS could be due to autoantibodies or direct neurotoxic effects of viruses.
Conclusion: Nervous system involvement in Covid-19 may have been grossly underestimated. In this era of pandemic, it is very important for the physicians to be aware of association of GBS with Covid-19, as early diagnosis and treatment of this complication could have gratifying results. To the best of our knowledge, this is the first such case series of Guillain-Barre Syndrome associated with Covid-19 to be reported from India.

1. Introduction
Globally, more than 12 million people have been infected with COVID − 19 infection till date with more than 500,000 fatalities [1]. Although, evolution in COVID-19 research is taking place at a rapid pace, new findings have to be thoroughly checked before any conclusion or treatment protocol is made or modified [2]. Although, Covid-19 commonly presents with marked respiratory symptoms in the form of cough and dyspnoea, a neurotropic presentation has been described of late as well [3]. Guillain Barre Syndrome (GBS) is best described as an acute inflammatory polyradiculoneuropathy clinically characterised by areflexia and progressive weakness of arms and legs. Though, many rare variants of GBS have been described, the commonly observed subtypes such as Acute Motor Axonal Neuropathy (AMAN), Acute Motor Sensory Axonal Neuropathy (AMSAN) and Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) tend to fulfil the above-mentioned criteria [4]. In this brief communication we report four cases of Covid-19 who presented to our hospital with features suggestive of GBS.

1.1. Case 1
A 55-year-old female with background history of Diabetes Mellitus, Hypertension and Cholelithiasis presented with chief complaints of fever 10 days back lasting for 3 days, pain abdomen for 5 days; acute onset rapidly progressive symmetric weakness of all four limbs for 3 days (lower limbs followed by upper limbs). There was no history suggestive of cranial nerve, bowel or bladder involvement. On examination, patient was hemodynamically stable with 98% oxygen saturation (SpO2) on room air. Cranial nerve examination was normal. Motor examination revealed generalised hypotonia, Grade 2/5 power in both lower limbs proximally and Grade 3/5 distally, while both upper limbs power was grade 4/5 proximally and grade 3/5 distally as per Medical Research Council (MRC) grading. Deep tendon reflexes were universally absent and plantar response was fl exor bilaterally. Sensory examination was normal. Her single breath count (SBC) was 26. Her routine blood investigations including complete blood count, liver and kidney function tests were normal. Viral markers including Human Immunodeficiency Virus, Hepatitis B Surface antigen (HBsAg) and Hepatitis C Virus (HCV) antibody were negative. Serum vitamin B12 levels and Thyroid function tests were normal whereas Glycosylated Hemoglobin (HbA1c) was elevated (9.4 %). Covid-19 testing was positive by reverse transcription polymerase chain reaction (RT-PCR). Inflammatory markers were universally elevated (Tables 1 and 2). Chest X ray was...
normal. Contrast enhanced Magnetic Resonance Imaging (MRI) of the spine was suggestive of degenerative changes in the spine (Table 2). Nerve Conduction Study (NCS) of both upper and lower limbs was suggestive of pure motor axonal polyneuropathy. CSF examination done on fourth day of hospitalisation showed albumino-cytological dissociation (Table 2). After informed consent the patient was started on IV Immunoglobulin (IVIG): 0.4 g/kg body weight per day for five days. In view of a possibility of Covid-19 associated hypercoagulable state (elevated D Dimer) she was also given therapeutic anticoagulation. There was no further progression of her symptoms after starting IVIG and the patient was discharged after 10 days of hospital stay with Grade 4/5 power in both lower limbs and Grade 4+/5 power in both upper limbs.

### Table 1
Clinical and laboratory parameters of four cases presenting with Covid-19 associated GBS.

| Case | Onset of neurological symptoms | Comorbidities | Cranial nerve involvement | Respiratory involvement | CRP levels (mg/L) | Ferritin levels (ng/ml) | IL-6 levels | D-dimer (FEU/ml) | LDH levels (U/L) |
|------|--------------------------------|---------------|---------------------------|-------------------------|--------------------|-------------------------|-------------|-----------------|-----------------|
| 1    | 10 days after onset of fever   | Diabetes mellitus | No                        | No                      | 9.4                | 382                     | 8.21        | 2.19            | 278             |
| 2    | 6 days after onset of fever    | Hypertension, Cholelithiasis | No                        | Yes (SRC = 12)          | 50                 | 482                     | 10.21       | 5.19            | 518             |
| 3    | One week after the onset of cough and sore throat | Diabetes mellitus | No                        | No                      | 34.41               | 560                     | 44.71       | 5.49            | 478             |
| 4    | 10 days after the onset of fever | Hypertension | Yes (Bilateral facial nerve palsy) | No                      | 0.96                | 322                     | 4.75        | 0.32            | 278             |

### 1.2. Case 2
A 72-year-old male, known case of hypertension for 5 years on treatment, presented to the emergency department of our hospital with chief complaints of fever 6 days back lasting for 2 days, cough since past 3 days associated with progressive weakness of all four limbs since past 2 days. He had lost the ability to walk independently since 1 day. There was no history suggestive of cranial nerve involvement, diarrhoea, bowel and bladder symptoms, or dog bite. On examination, patient was hemodynamically stable and afebrile. Neurological examination revealed no cranial nerve involvement. Motor examination showed generalised hypotonia, Grade 2/5 power in both lower limbs and grade 3/5 in both upper limbs as per MRC grading. Deep

### Table 2
Laboratory parameters, Imaging and clinical outcomes of four cases presenting with Covid-19 associated GBS.

| Case | Chest X ray | NCS findings | CSF | MRI spine | Treatment | Outcome |
|------|------------|--------------|-----|-----------|-----------|---------|
| 1    | Normal     | Pure motor axonal polyneuropathy | Protein: 54 mg% Glucose: 114 mg% Cells = 5 cells/cmm; all lymphocytes | Mild degenerative changes. No Cord changes No nerve root enhancement | IVIG: 2 g/kg over 5 days | Good improvement ( Able to walk independently at discharge) |
| 2    | Ill-defined inhomogeneous infiltrates involving predominantly the upper lobes | Severe demyelinating sensorimotor polyneuropathy affecting all 4 limbs with evidence of conduction block involving both ulnar nerves. | Protein: 74 mg% Glucose: 110 mg% Cells = 0 cells/cmm. | Mild degenerative changes. No Cord changes No nerve root enhancement | IVIG: 2 g/kg over 5 days with supportive treatment | Deteriorated over the course of treatment. |
| 3    | Normal     | Axonal sensorimotor polyneuropathy affecting all 4 limbs | Protein: 84 mg% glucose: 94 mg% Cells = 5 cells/cmm; all lymphocytes | Mild degenerative changes. No Cord changes No contrast enhancement | IVIG: 2 g/kg over 5 days | Good improvement ( Able to walk independently at discharge) |
| 4    | Bilateral lower and midzone infiltrates | Pure motor demyelinating polyneuropathy involving all 4 limb and | Protein: 52 mg%; Glucose: 54 mg% | Mild degenerative changes. | IVIG: 2 g/kg over 5 days | Good improvement ( Able to walk independently at discharge) |
tendon reflexes were universally absent and plantar response was flexor bilaterally. The sensory examination was normal. His SBC was 12. His routine blood investigations including complete blood count, serum sodium and potassium, liver and kidney function tests were normal. Viral markers including Human Immunodeficiency Virus, Hepatitis B Surface antigen (HBsAg) and Hepatitis C Virus (HCV) antibody were negative. Serum B12 levels and Thyroid function tests were normal. Covid-19 testing was positive by RT-PCR technique. Contrast MRI of whole spine was suggestive of degenerative changes in the spine (Table 2). CSF examination showed albumino-cytological dissociation and inflammatory markers were elevated (Tables 1 and 2). Chest X-ray showed bilateral ill-defined inhomogeneous infiltrates involving predominantly the upper lobes. IVIG therapy was started at a dose of 0.4 g/kg/day for five days. NCS was suggestive of severe demyelinating sensori-motor polyneuropathy affecting all 4 limbs with evidence of conduction block involving both ulnar nerves. Despite being on IVIG and supportive treatment for Covid-19, the patient had worsening of power in both upper and lower limbs and developed severe respiratory distress requiring intubation and mechanical ventilation. His respiratory involvement (chest infiltrates due to Covid-19) also continued to worsen and the patient expired after 7 days of hospital admission.

1.3. Case 3

A 55-year-old male, known case of Diabetes mellitus, hypertension and chronic kidney disease on maintenance haemodialysis (3/week) presented to OPD with chief complaints of difficulty in walking since 3 days and mild weakness of upper extremities since 1 day. He had history of cough and sore throat 1 week back for 2 days. There was no history suggestive of cranial nerve involvement, diarrhoea, bowel and bladder symptoms, or dog bite. On examination, patient was hemodynamically stable and afebrile. Neurological examination revealed no cranial nerve involvement. Motor examination showed generalised hypotonia, grade 3/5 power in both lower limbs proximally and 4−/5 distally. Upper limb motor examination showed grade 4/5 power bilaterally as per MRC grading. Deep tendon reflexes were absent in both lower limbs and 1+ in both upper limbs. Plantar response was flexor bilaterally. The sensory examination was abnormal with glove and stocking pattern sensory loss (position sense and pain) and positive Romberg's test. His SBC was 22. He underwent routine blood investigations which showed microcytic/hypochromic anaemia, raised blood Urea (61 mg/dL) and Creatinine levels (4.74 mg/dL). Potassium was elevated (5.82 mmol/L) with elevated HbA1c (8.4 %). Viral markers including HIV, HBsAg and HCV antibody were negative. Serum vitamin B12 levels and Thyroid function tests were normal. Covid-19 testing was positive by RT-PCR technique. MRI screening of whole spine showed mild degenerative changes with no cord hyperintensity (Table 2). CSF examination showed albumino-cytological dissociation with elevated inflammatory markers (Tables 1 and 2). Chest X-ray was normal. NCS was suggestive of axonal sensorimotor polyneuropathy affecting all 4 limbs. IVIG therapy was started on Day 2 of hospital admission and 2 g/kg body weight of same was given over 5 days. Patient had good neurological improvement and was discharged by 9th day with power of grade 4+/5 in both upper limbs and grade 4/5 in both lower limbs.

1.4. Case 4

A 49-year-old male, known case of hypertension on treatment, presented to the neurology outpatient department (OPD) with chief complaints of fever 10 days back which lasted for 2 days followed by 4 days history of progressive lower limb weakness and 2 days history of facial weakness. On examination, patient was hemodynamically stable, afebrile with 98% SpO2 on room air. Neurological examination revealed bilateral lower motor neuron facial palsy (right > left). Upper limb power was normal across all joints; both lower limb power:

proximal: 3/5; distal: 4/5 as per MRC grading. The Deep tendon reflexes were absent in lower limbs and normal in upper limbs. Sensory examination was normal. Routine blood investigations including complete blood count, serum sodium and potassium, liver and kidney function tests were normal. Viral markers including HIV, HBsAg and HCV antibody were negative. Serum vitamin B12 levels and Thyroid function tests were normal. Covid-19 testing was positive by RT-PCR technique. NCS was suggestive of pure motor demyelinating polyneuropathy involving all 4 limbs. Contrast MRI of whole spine showed mild degenerative changes of the spine (Table 2). CSF examination showed albumino-cytological dissociation with mildly elevated inflammatory markers in the blood (Tables 1 and 2). Chest X-ray showed evidence of bilateral lower and midzone infiltrates. IVIG was given at 0.4 g/kg body weight/day for 5 days with other supportive treatment. Good neurological improvement was observed over the next 5 days and patient was discharged after 7 days. At the time of discharge patient had 4+/5 power in both lower limbs with mild residual facial palsy.

2. Discussion

A member of the beta-coronaviridae family, SARS-CoV-2 is an enveloped, non-segmented, single-stranded, positive-sense RNA virus. The mechanisms by which SARS-CoV-2 causes neurologic damage are multifaceted, including direct damage to specific receptors, cytokine-related injury, secondary hypoxia, and retrograde travel along nerve fibres [5]. Three of the above cases presented with neurological complaints and had no respiratory features secondary to Covid-19, and these were the ones who did quite well with treatment. One patient who presented with respiratory complaints and X-ray changes along with neurological deficits continued to deteriorate even after starting treatment for both GBS and Covid-19, and eventually succumbed to the disease.

In the past GBS has been associated with a number of viral infections, most recently to Zika virus [6]. The pathogenesis of GBS secondary to Covid-19 is not well understood. It is well documented that the cross immunity which plays an important role in GBS secondary to bacterial infections such as C. jejuni may not be the main reason behind GBS associated with viral infections namely Dengue and Zika. It is hypothesised that viral illnesses related GBS could be due to autoantibodies or direct neurotoxic effects of viruses [7]. Although, our patients had positive PCR throat swab test, their CSF examination did not show any raised cell count and contrast MRI of the spine did not show any enhancement of caudal nerve roots, thus favouring immune mediated hypothesis. This was further strengthened by an excellent response to IVIG, thus favouring an immune mediated pathogenesis rather than direct viral damage.

Our case series serves to highlight the heterogeneity in clinical presentation and laboratory parameters of patients with Covid-19 associated GBS (Tables 1 and 2). Only one of our patients had cranial nerve involvement (bilateral facial nerve palsy) with no patient developing bulbar symptoms. This was in contrast to typical GBS, wherein cranial nerve involvement is quite common. Less frequent involvement of cranial nerves in GBS secondary to Covid-19 is also in contrast to Zika virus associated GBS, where facial and third nerve involvement was quite common [7]. All the above patients had significantly raised pro-inflammatory markers that might suggest a causal link to pro-inflammatory state secondary to Covid-19. Similar rise in inflammatory markers were noted in other case reports as well, and it was hypothesised that these inflammatory mediators and cytokines may play a role in triggering an immune mediated neuropathy [8].

All our patients developed features of GBS, 5−10 days after the onset of Covid-19 symptoms, which is similar to the interval seen with Guillain–Barré syndrome that occurs secondary to other infections [9]. Most of the previous case reports documented a similar interval duration between the onset of Covid-19 symptoms and GBS [2,9]. Three of our patients had an excellent response to IVIG and were ambulatory.
3. Conclusion

Nervous system involvement in Covid-19 may have been grossly underestimated. Over the course of this pandemic, an increasing number of Covid-19 patients are being reported with neurological complications. Some of these neurological presentations, in particular GBS has quite effective treatment options. In this era of pandemic, it is very important for the physicians to be aware of the association of GBS with Covid-19, as early diagnosis and treatment of this complication could have gratifying results. It is also important to differentiate GBS from critical illness neuropathy and respiratory distress secondary to Covid-19 itself, as treatment to the above conditions is quite different and inability to correctly diagnose could lead to significant increase in morbidity and mortality. To the best of our knowledge this case series of Guillain-Barre Syndrome associated with Covid-19 is the first one to be reported from India.

Declaration of Competing Interest

The manuscript, as submitted or its essence in another version, is not under consideration for publication elsewhere, and will not be published elsewhere while under consideration by AJEM. The authors have no commercial associations or sources of support that might pose a conflict of interest. All authors have made substantive contributions to the study, and all authors endorse the data and conclusions.

References

[1] World Health Organization. Coronavirus Disease (COVID-19): Situation Report, 172; 2020.
[2] Carrillo-Larco RM, Alvez-Fernandez C, Ravaglia S, Vizcarra JA, COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. Wellcome Open Res. 2020;5:107.
[3] Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):1–9.
[4] Piccione EA, Salame K, Katriji B. Guillain-Barré syndrome and related disorders. Neuromuscular disorders in clinical practice. New York, NY: Springer; 2014. p. 573–603.
[5] Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. Ann J Emerg Med. 2020;38(7):1549.e3–7.
[6] Virani A, Rabold E, Hanson T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. IDCases. 2020;20:e00771.
[7] Gupta A, Paliwal VK, Garg RK. Is COVID-19-related Guillain-Barré syndrome different? Brain Behav Immun. 2020;87:177–8.
[8] Benverusuto Angelo, Carella Angelo Michele, et al. Atypical clinical presentation of COVID-19: a case of Guillain-Barré syndrome related to SARS-CoV-2 infection. Curr Tr Clin Med Sci. 2020;2(1).
[9] Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574–6.
[10] Assini A, Benedetti I, Di Maio S, Schirinzi E, Del Sette M. New clinical manifestation of COVID-19 related Guillain-Barré syndrome highly responsive to intravenous immunoglobulins: two Italian cases [published correction appears in Neurol Sci. 2020 Jun 8]. Neurol Sci. 2020;41(7):1657–8.